Back to News
Market Impact: 0.4
Eli Lilly: Mounjaro And Zepbound Keep The Growth Story Alive
Source: seekingalpha.com
Corporate EarningsHealthcare & BiotechCompany Fundamentals
Eli Lilly reported Q3 non-GAAP EPS growth of 6.6% and revenue growth of 38.6% year over year. Combined Mounjaro and Zepbound sales reached $16.08 billion, up 59.1% year over year.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
LLY0.65
More News
- Alphabet’s stock has worst day in over 20 years, dragging the S&P 500 to first loss in four days
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
- Lilly’s obesity drug strength fuels record rally, Wall Street optimism
- Nasdaq futures slide as mixed Big Tech results test AI trade
- Stocks making the biggest moves midday: ADT, Alphabet, Caterpillar, Eli Lilly, Chipotle & more